Researchers from India have also made remarkable contributions to the literature on mCRPC treatment with225Ac-PSMA-617.80, 81, 82, 83Xerostomia is a common treatment-related toxicity seen in almost all patients treated with225Ac-PSMA-617.73, 84Owing to the significant impact xerostomia may have on the quality of life, there is a concern that treatment with225Ac-PSMA-617 may significantly reduce the quality of life despite a favorable disease response to treatment. Here, FOLH1 is linked to xerostomia.